lacosamide / Generic mfg. - LARVOL DELTA

Lacosamide versus topiramate in episodic migraine: a randomized controlled double-blinded trial. (PubMed, Ther Adv Neurol Disord) - P3 | "Lacosamide was more tolerable than topiramate in episodic migraine patients. Prospectively registered on clinicaltrials.gov, NCT06243692-January 29, 2024; https://clinicaltrials.gov/study/NCT06243692."

Journal • CNS Disorders • Epilepsy • Migraine • Pain • CRMP

Quality of life and synergistic combinations of antiseizure medication in patients treated with cenobamate in early therapy lines for focal-onset seizures. (PubMed, Epilepsy Behav) - "Our study provides evidence that CNB in early therapy lines for focal-onset seizures is associated with an increased HrQoL. Low-dose clobazam can wok synergistically with CNB. The combination with SV2A modulators showed a positive trend."

HEOR • Journal • CNS Disorders • Epilepsy

Combination of two Na+ channel-inhibiting anticonvulsants lacosamide and phenytoin: An additive, synergistic, or antagonistic effect? (PubMed, Biochem Pharmacol) - "On the other hand,the rare cardiac adverse events reported for LCM use is not expected to increase with the combination because of the little additive effect on intermediate inactivated states. Abbreviations: AUC, area-under-the-curve; ANOVA, analysis of variance; CA1, cornu ammonis area 1 of the hippocampus; CHO-K1, Chinese hamster ovary K1; CI, combination index; DPH, phenytoin; EEG, electroencephalography; FBS, fetal bovine serum; GFP, green fluorescent protein; If, fast inactivated states; Ii, intermediate inactivated states; Is, slow inactivated states; LCM, lacosamide; Nav1.7, voltage-gated sodium channel subtype 1.7; SEM, standard error of the mean."

Journal • CNS Disorders • Epilepsy • NAV1

Lacosamide-Induced Drug Rash With Eosinophilia and Systemic Symptoms Syndrome in a Pediatric Patient: A Case Report. (PubMed, Pediatr Neurol) - No abstract available

Journal • Eosinophilia • Pediatrics

A Multifaceted Case of CASPR2 Antibody-Associated Autoimmune Encephalitis Presenting with Gait Disturbances, Visual Abnormalities, and Temporal Lobe Epilepsy (AES 2025) - "Levetiracetam was started but later switched to lacosamide due to adverse mood effects...The patient had significant improvement of dizziness, gait disturbance and cognition following 5 days of high-dose intravenous methylprednisolone followed by oral prednisone taper...Steroid therapy was re-escalated, and the patient was scheduled for initiation of rituximab. This case underscores the diagnostic challenges posed by CASPR2 antibody-associated autoimmune encephalitis, particularly when presenting with non-specific symptoms of orthostatic hypotension and suspected peripheral neuropathy in the context of unrevealing imaging. Early clinical suspicion and initiation of immunotherapy are critical to optimizing neurologic and functional outcomes."

Clinical • Alzheimer's Disease • Cardiovascular • CNS Disorders • Cognitive Disorders • Coronary Artery Disease • Epilepsy • Hypertension • Hypotension • Immunology • Thrombosis • CNTN

Rapid response to encorafenib and binimetinib (Enc/Bini) in a patient with recurrent ganglioglioma with leptomeningeal spread (SNO 2025) - "Initial treatment included surgical resection, followed by concurrent radiation and temozolomide (TMZ). She initiated anti-BRAFV600E therapy with dabrafenib and trametinib but was intolerant due to intractable flu-like symptoms including fever, rash and fatigue...Ocular and generalized seizures resolved with targeted treatment and transition to lacosamide...Prior studies in patients with primary CNS tumors and brain metastases have demonstrated encouraging responses and overall tolerability with this regimen. To our knowledge, this represents the first documented case of a rapid and durable (four months to date) clinical and radiographic response to systemic BRAF-targeted therapy in a patient with recurrent-AGG and leptomeningeal spread."

Clinical • Brain Cancer • CNS Disorders • CNS Tumor • Epilepsy • Ganglioglioma • Glioma • Mood Disorders • Ophthalmology • Otorhinolaryngology • Solid Tumor • APC • CDKN2A • CDKN2B

Retrospective study of trigeminal neuralgia: Analysis of 100 episodes managed in the emergency department (EHF-EHC 2025) - "The most frequently prescribed treatment by neurologists was lacosamide, with a pain relief rate of 84.6%, whereas emergency physicians predominantly administered paracetamol, NSAIDs, and opioids...Trigeminal neuralgia poses a significant challenge in the emergency setting, with considerable heterogeneity in both its diagnostic and therapeutic management, and a high proportion of initial diagnoses not subsequently confirmed. This study underscores the importance of neurological assessment in the emergency department and the need for close follow-up to optimize symptom control"

Retrospective data • Neuralgia • Pain

Association between the clinical profile of patients with trigeminal neuralgia and treatment resistance: Case series analysis (EHF-EHC 2025) - "These findings suggest that standard clinical characteristics may not fully explain therapeutic response, emphasizing the need for individualized treatment strategies and further research into predictive biomarkers. Preliminary observations also support further investigation of lacosamide as a potential first-line treatment option.""

Clinical • Neuralgia • Pain

Rapid response to encorafenib and binimetinib (Enc/Bini) in a patient with recurrent ganglioglioma with leptomeningeal spread (WFNOS 2025) - "Initial treatment included surgical resection, followed by concurrent radiation and temozolomide (TMZ). She initiated anti-BRAFV600E therapy with dabrafenib and trametinib but was intolerant due to intractable flu-like symptoms including fever, rash and fatigue...Ocular and generalized seizures resolved with targeted treatment and transition to lacosamide...Prior studies in patients with primary CNS tumors and brain metastases have demonstrated encouraging responses and overall tolerability with this regimen. To our knowledge, this represents the first documented case of a rapid and durable (four months to date) clinical and radiographic response to systemic BRAF-targeted therapy in a patient with recurrent-AGG and leptomeningeal spread."

Clinical • Brain Cancer • CNS Disorders • Epilepsy • Ganglioglioma • Glioma • Mood Disorders • Oncology • Ophthalmology • Otorhinolaryngology • Psychiatry • Solid Tumor • APC • CDKN2A • CDKN2B

Investigation of Lacosamide solubility in supercritical carbon dioxide with machine learning models. (PubMed, Sci Rep) - "The findings suggested that all applied models were competent in providing reliable predictions, with GBDT (R2 = 0.9989), XG Boost (R2 = 0.9986), and MLP (R2 = 0.9975) exhibiting the highest accuracy, achieving the highest coefficient of determination (R2). Overall, combining experimental data with advanced machine learning algorithms offers a powerful approach for predicting and optimizing drug solubility in supercritical systems, thereby facilitating the design of scalable pharmaceutical processes."

Journal

Real-world evidence on the use of new antiseizure medications in brain tumor-related epilepsy. (PubMed, Epilepsy Res) - "Newer ASMs demonstrated favorable seizure control and tolerability in BTRE. LEV remains the most used agent, though LTG and LCS showed comparable efficacy. Tumor and treatment-related factors influenced outcomes more than ASM choice."

HEOR • Journal • Real-world evidence • Brain Cancer • CNS Disorders • Epilepsy • Oncology • Solid Tumor

Pre-Ictal Asystole in Refractory Epilepsy: A Video Case Report (AES 2025) - "Medications included lacosamide and lamotrigine...The patient was discharged on Perampanel 4 mg daily, and according to the parent's report on a follow up visit, there has been significant improvement, with no new seizures of any type observed. Our case is unique given a long pre-ictal asystole, as most literature regarding ictal asystole suggests it occurs at or following ictal onset... Our case is unique given a long pre-ictal asystole, as most literature regarding ictal asystole suggests it occurs at or following ictal onset. While the asystole in our case occurred during lab draws, the preceding junctional rhythms and pauses suggest a more complex interplay between autonomic instability and this seizure's onset rather than vasovagal response. Also, lack of EEG changes prior to and during asystole suggest against hypoperfusion-induced seizure."

Case report • Clinical • Video • Cardiovascular • CNS Disorders • Epilepsy

Cenobamate in real world : a single center study (AES 2025) - "68 patients had a proactive decrease in one or several concomitant ASM dosage, mainly lacosamide (N=25), perampanel (N=14), clobazam (N=12). 51 patients needed a further decrease in other ASM dosage (mainly brivaracetam and lacosamide), and 52 patients could stop at least one concomitant ASM (mainly lacosamide and perampanel)... Efficacy of CNB is confirmed in this real world series of patients. After one year of follow up, the efficacy is maintained with 52% of the patients being either seizure free or responders. Side effects are common and in line with those found in regulatory studies."

Clinical • Real-world • Real-world evidence • Ataxia • CNS Disorders • Epilepsy • Movement Disorders

Seizure Freedom with Nicotine Patch in a Child with CHRNB2 Mutation and Sleep Related Hyper Motor Epilepsy: A Case Report (AES 2025) - "Incremental increases in levetiracetam to 60mg/kg/day failed to control the child's seizures...Seizures did not respond to 10mg/kg/day lacosamide nor to clonazepam... There have been no other cases in the literature with a pathogenic variant of CHRNB2 heterozygous mutation with SHE, who achieved complete seizure freedom after initiating treatment with transdermal nicotine patch. Our patient's case is a rare example of such a response with supporting video EEG and quantitative EEG evidence."

Case report • Clinical • CNS Disorders • Epilepsy • Infectious Disease

Long-Term Use of Oral Lacosamide in Young Children With Epilepsy Who Received Lacosamide in Previous Trials: Data From a Multicenter, Open-Label, Follow-Up Trial (AES 2025) - P3 | "Long-term LCM treatment of children with epilepsy (< 6 years of age at trial entry) was well tolerated and no new safety signals were identified."

Clinical • Cardiovascular • CNS Disorders • Congestive Heart Failure • Developmental Disorders • Epilepsy • Heart Failure • Infectious Disease • Respiratory Diseases

Temporal Lobe Laser Ablation as Treatment for Epilepsy in Koolen deVries Syndrome: A Case Report (AES 2025) - "Seizure frequency included one to two breakthrough seizures monthly despite polytherapy with ASMs including clonazepam, zonisamide, and lacosamide. This case demonstrates that surgical interventions done for patients with more common forms of epilepsy, such as temporal lobe laser ablations, can also be effective treatment options for patients with Koolen de-Vries Syndrome (KdVS)-associated epilepsy as well. Our patient achieved seizure freedom for at least 12 months following surgery with no significant adverse effects. These findings suggest that surgical evaluation should be considered in KdVS patients with medication-resistant epilepsy and correlating EEG and MRI abnormalities."

Case report • Clinical • CNS Disorders • Developmental Disorders • Dystonia • Epilepsy • Mental Retardation • Movement Disorders • Psychiatry • KANSL1

Assessment of Adjunct Cenobamate on Seizure Outcome Using Long-term Electrocorticography (AES 2025) - "Table of Results LCM – Lacosamide ESL – Eslicarbazepine CBZ – Carbamazepine Long-term ECoG offers an objective method to assess antiseizure medication efficacy. Long-term ECoG offers an objective method to assess antiseizure medication efficacy. However, it also presents challenges such as inconsistent interrogation and uploads, resulting in a smaller sample size. In this retrospective analysis, 85% of patients treated with both CNB and RNS demonstrated a reduction in seizure count."

CNS Disorders • Epilepsy

Multi-Night Analysis on the Effect of Epilepsy Medication on Sleep Spindles in Intracranial EEG (AES 2025) - "Each patient took between 1-4 anti-epilepsy medications, which included Lamotrigine, Topiramate, Cenobamate, Clobazam, Oxcarbazepine, Briviact, Carbamazepine, Lacosamide, and Zonisamide. This preliminary analysis into muti-medication effects on sleep spindles during a multi-night EMU stay with intracranial EEG, suggests that there could be a relationship between anti-epilepsy medication dosages and sleep spindle rates. If confirmed in a larger cohort, the observed increase in sleep spindle rate with higher medication doses might suggest a positive effect of medication on sleep. This could be an indirect consequence of the decrease in epileptiform activity, which might permit the augmentation of sleep spindles even outside the seizure onset zone."

CNS Disorders • Epilepsy

Extending Epilepsy and Pregnancy Registers: A Pilot in The UK Epilepsy and Pregnancy Register to Include Routine Longitudinal Child Follow Up (AES 2025) - "These numbers included rarer ASM exposures such as clobazam, cenobamate, zonisamide, lacosamide and brivaracetam. A dual model of both surveillance and enhanced investigations offers the opportunity to routinely collect screening level child health and neurodevelopmental outcome data across large geographical regions, alongside more enhanced researcher-led data collection for subpopulations. Implementing longitudinal routine child health and neurodevelopmental investigations into already established initiatives such as Epilepsy and Pregnancy Registers will improve available data regarding the safe use of ASMs in women of reproductive age."

Clinical • CNS Disorders • Epilepsy

Intracranial Electrophysiological Investigation during Cardiac Arrest: A Case Study (AES 2025) - "Analyses included spectral decomposition using Morlet wavelets, power spectrum density (PSD), and functional connectivity by correlating the low frequency fluctuations (0.1-1 Hz) of high-frequency activity (HFA, 70-200 Hz). Admission medications included Oxcarbazepine, Levetiracetam and Lacosamide. Intracranial EEG during the transition to brain death due to cerebral edema showed progressive slowing, increased functional connectivity, and eventual network collapse. The findings may support future biomarker development for improved risk assessment and intervention strategies. This is the first intracranial EEG study to analyze the spectral and network level changes during cardiac arrest and brain death."

Case study • Clinical • Cardiovascular • CNS Disorders • Depression • Epilepsy • Psychiatry

The Effect of the Antiepileptic Drug Lacosamide on an Aβ1-42 oligomer-treated AD Neuronal Cell Model (AES 2025) - "Nav1.6 channels, which are associated with nervous system excitability, were significantly increased in the AD cell model. LCM, a novel antiepileptic drug, partially ameliorated the elevated Nav1.6 channels and elevated neuronal excitability in the AD cell model and LCM has the potential to treat AD combined with epilepsy by a mechanism that may involves the alteration of Nav1.6 channels."

Alzheimer's Disease • CNS Disorders • Epilepsy • Aβ42 • NAV1

Mid-South Single Center Experience of Status Epilepticus with Autoimmune Encephalitis (AES 2025) - "The patient with anti-ganglionic nicotinic ACh receptor encephalitis presented with seizures along with focal motor weakness developed cardiac arrest possibly due to autonomic dysfunction [5], resuscitated and later improved with PLEX and IVIG followed by immunosuppression with mycophenolate mofetil. The seizures were treated predominantly with levetiracetam, lacosamide, phenobarbital and perampanel. Our retrospective case series study showed that despite having long ICU stay and ventilator days, 85% of the patients with new onset refractory status epilepticus due to autoimmune encephalitis improved with high dose steroids, PLEX and/ or IVIG except for one patient with anti-NMDA receptor positive with extreme delta brush pattern who died [3]. EBV IgG positive in CSF in one patient with anti-NMDA receptor encephalitis suggests the possibility of EBV infection being trigger for anti-NMDA encephalitis[4]."

Clinical • Cardiovascular • CNS Disorders • Epilepsy • Epstein-Barr Virus Infections • Immunology • Infectious Disease • Psychiatry • Respiratory Diseases

Vagus Nerve Stimulator Placement in a 7-Month-Old with GABRB3 Pathogenic Variant: A Case Report (AES 2025) - "Despite trials of multiple anti-seizure medications (Levetiracetam, Phenobarbital, Felbamate, Clobazam, and Lacosamide) and initiation of the ketogenic diet, seizures persisted ( >20/day) and were accompanied by developmental regression. This case illustrates the potential efficacy and tolerability of VNS in an infant under one year of age with drug-resistant epilepsy due to a GABRB3 pathogenic variant. The patient eventually became seizure free after VNS modification to rapid cycling and weaning all seizure medication. Although data remains sparse for this population, both the age and genetic variant, our findings support the consideration of VNS as an early intervention in infants under 1 year of age with medically refractory epilepsy."

Case report • Clinical • CNS Disorders • Epilepsy

Progressive Hemispheric Atrophy and Movement Disorder in Adult-Onset Rasmussen Encephalitis: A Case Report and Literature Review (AES 2025) - "Her antiseizure regimen was escalated to include levetiracetam 1000 mg three times daily, lacosamide 200 mg twice daily, and divalproex 500 mg three times daily.Over the following five years, she developed aphasia, right-sided dystonia, choreoathetosis, bilateral tremors, parkinsonian features, and vertical nystagmus. Lacosamide was replaced by Oxcarbazepine 600 mg twice daily, but she continued to experience 4–5 generalized tonic-clonic seizures every three months... Adult-onset Rasmussen encephalitis should be considered in adults presenting with progressive unilateral cortical atrophy, drug-resistant focal seizures, and emerging movement or cognitive deficits. Timely initiation of treatment may provide meaningful clinical improvement and significantly enhance quality of life."

Case report • Clinical • IO biomarker • Review • CNS Disorders • Cognitive Disorders • Depression • Dystonia • Epilepsy • Huntington's Disease • Immunology • Movement Disorders • Ophthalmology • Parkinson's Disease • Postpartum Depression • Psychiatry

Expanding the Phenotype of CALM1-Associated LQT14: First Report of Focal Epilepsy (AES 2025) - "Levetiracetam significantly worsened QTc. Oxcarbazepine had no effect on QTc but was stopped due to rash. Lacosamide was initiated at 3 mg/kg/day with seizure control for over 20 months... This case demonstrates a possible association between CALM1-gene function and central nervous system regulation. Calmodulin dysregulation may contribute to epileptogenesis by disrupting calcium signaling and altering the function of voltage-gated ion channels. To our knowledge, this represents the first reported case of focal epilepsy in a patient with CALM1-associated long QT syndrome type 14 (LQT14), thereby expanding the phenotypic spectrum of CALM1-related disorders to include focal epilepsy."

Cardiovascular • CNS Disorders • Epilepsy • Ventricular Tachycardia • CALM1 • CALM2